Pharmacokinetics, Safety, and Tolerability of Oral Semaglutide in Subjects With Hepatic Impairment

Tine A Baekdal, Mette Thomsen, Viera Kupčová, Cilie W Hansen, Thomas W Anderson, Tine A Baekdal, Mette Thomsen, Viera Kupčová, Cilie W Hansen, Thomas W Anderson

Abstract

Semaglutide is a human glucagon-like peptide-1 analog that has been co-formulated with the absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, for oral administration. This trial (NCT02016911) investigated whether hepatic impairment affects the pharmacokinetics, safety, and tolerability of oral semaglutide. Subjects were classified into groups: normal hepatic function (n = 24), and mild (n = 12), moderate (n = 12), or severe (n = 8) hepatic impairment according to Child-Pugh criteria, and received once-daily oral semaglutide (5 mg for 5 days followed by 10 mg for 5 days). Semaglutide plasma concentrations were measured during dosing and for up to 21 days post-last dose. Area under the semaglutide plasma concentration-time curve from 0-24 hours after the 10th dose (primary end point) and maximum semaglutide concentration after the 10th dose appeared similar across hepatic function groups. Similarly, there was no apparent effect of hepatic impairment on time to maximum semaglutide concentration (median range 1.0-1.5 hours) or half-life (geometric mean range 142-156 hours). No safety concerns were identified in subjects with hepatic impairment receiving semaglutide. Reported adverse events were in line with those observed for other glucagon-like peptide-1 receptor agonists. There was no apparent effect of hepatic impairment on the pharmacokinetics, safety, and tolerability of oral semaglutide. The results of this trial suggest that dose adjustment of oral semaglutide is not warranted in subjects with hepatic impairment.

Keywords: GLP-1 receptor agonists; hepatic impairment; pharmacokinetics; semaglutide.

© 2018, The Authors. The Journal of Clinical Pharmacology published by Wiley Periodicals, Inc. on behalf of American College of Clinical Pharmacology.

Figures

Figure 1
Figure 1
Trial design. PK, pharmacokinetics.
Figure 2
Figure 2
Geometric mean concentration–time profiles of semaglutide after the 10th dose, by hepatic function group. Full analysis set.
Figure 3
Figure 3
AUC0–24h,Day10 and Cmax,Day10 for semaglutide after the 10th dose, by hepatic function group. Full analysis set. Bars are estimated means and 95%CI. Treatment comparisons show estimated treatment ratio and 90%CI. AUC, area under the semaglutide plasma concentration–time curve; CI, confidence interval; Cmax, maximum semaglutide concentration.
Figure 4
Figure 4
Mean concentration–time profiles of SNAC after the 10th dose, by hepatic function group. Full analysis set. SNAC, sodium N‐(8‐[2‐hydroxybenzoyl] amino) caprylate.
Figure 5
Figure 5
AUC0–24h,Day10 and Cmax,Day10 for SNAC after the 10th dose, by hepatic function group. Full analysis set. Bars are estimated means and 95%CI. Treatment comparisons show estimated treatment ratio and 90%CI. AUC, area under the plasma concentration–time curve; CI, confidence interval; Cmax, maximum concentration; SNAC, sodium N‐(8‐[2‐hydroxybenzoyl] amino) caprylate.

References

    1. Carls G, Huynh J, Tuttle E, Yee J, Edelman SV. Achievement of glycated hemoglobin goals in the US remains unchanged through 2014. Diabetes Ther. 2017;8:863–873.
    1. Drucker DJ, Nauck MA. The incretin system: glucagon‐like peptide‐1 receptor agonists and dipeptidyl peptidase‐4 inhibitors in type 2 diabetes. Lancet. 2006;368:1696–1705.
    1. Verspohl EJ. Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon‐like peptide‐1 receptor agonists) and dipeptidyl peptidase‐4 inhibitors. Pharmacol Ther. 2009;124:113–138.
    1. Blundell J, Finlayson G, Axelsen M, et al. Effects of once‐weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab. 2017;19:1242–1251.
    1. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient‐centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38:140–149.
    1. American Diabetes Association . 8. Pharmacologic approaches to glycemic treatment. Diabetes Care. 2017;40(suppl 1): S64–S74.
    1. Ismail R, Csóka I. Novel strategies in the oral delivery of antidiabetic peptide drugs ‐ insulin, GLP 1 and its analogs. Eur J Pharm Biopharm. 2017;115:257–267.
    1. Lau J, Bloch P, Schäffer L, et al. Discovery of the once‐weekly glucagon‐like peptide‐1 (GLP‐1) analogue semaglutide. J Med Chem. 2015;58:7370–7380.
    1. Kapitza C, Nosek L, Jensen L, Hartvig H, Jensen CB, Flint A. Semaglutide, a once‐weekly human GLP‐1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel. J Clin Pharmacol. 2015;55:497–504.
    1. Buckley ST, Schéele SG, Kirk RK, Knudsen LB. Mechanism of absorption mediated by SNAC in an oral formulation of semaglutide. Diabetes. 2017;66(suppl 1):1206‐P.
    1. Connor A, Borregaard J, Buckley ST, et al. Site of absorption of an oral formulation of semaglutide. Diabetes. 2017;66(suppl 1):1180‐P.
    1. Scheen AJ. Pharmacokinetics in patients with chronic liver disease and hepatic safety of incretin‐based therapies for the management of type 2 diabetes mellitus. Clin Pharmacokinet. 2014;53:773–785.
    1. Jensen L, Helleberg H, Roffel A, et al. Absorption, metabolism and excretion of the GLP‐1 analogue semaglutide in humans and nonclinical species. Eur J Pharm Sci. 2017;104:31–41.
    1. Jensen L, Kupcova V, Arold G, et al. Pharmacokinetics and tolerability of semaglutide in people with hepatic impairment. Diabetes Obes Metab. 2018;20:998–1005.
    1. US Department of Health and Human Services Food and Drug Administration . Center for Drug Evaluation and Research. Guidance for industry. Pharmacokinetics in patients with impaired hepatic function – study design, data analysis and impact on dosing and labeling. . Published May 2003. Accessed August 2017.
    1. European Medicines Agency. Committee for Medicinal Products for Human Use . Guideline on the evaluation of the pharmacokinetics of medicinal products in patients with impaired hepatic function. . Published February 2005. Accessed August 2017.
    1. Bækdal TA, Blicher TM, Donsmark M, Søndergaard FL. Safety, tolerability, and pharmacokinetics of single escalating doses of oral semaglutide in healthy male subjects. Diabetes. 2017;66(suppl 1):1191‐P.
    1. Marbury TC, Flint A, Jacobsen JB, Derving Karsbøl J, Lasseter K. Pharmacokinetics and tolerability of a single dose of semaglutide, a human glucagon‐like peptide‐1 analog, in subjects with and without renal impairment. Clin Pharmacokinet. 2017;56:1381–1390.
    1. Seaquist ER, Anderson J, Childs B, et al. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care. 2013;36:1384–1395.
    1. Flint A, Nazzal K, Jagielski P, Hindsberger C, Zdravkovic M. Influence of hepatic impairment on pharmacokinetics of the human GLP‐1 analogue, liraglutide. Br J Clin Pharmacol. 2010;70:807–814.
    1. Victoza Summary of Product Characteristics. . Accessed November 2017.
    1. Armstrong MJ, Gaunt P, Aithal GP, et al. Liraglutide safety and efficacy in patients with non‐alcoholic steatohepatitis (LEAN): a multicentre, double‐blind, randomised, placebo‐controlled phase 2 study. Lancet. 2016;387:679–690.
    1. Davies M, Pieber TR, Hartoft‐Nielsen ML, Hansen OKH, Jabbour S, Rosenstock J. Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes: a randomized clinical trial. JAMA. 2017;318:1460–1470.
    1. Granhall C, Donsmark M, Golor G, Søndergaard FL, Thomsen M. Safety, tolerability, and pharmacokinetics of multiple once‐daily dosing of oral semaglutide in healthy males and in males with T2D. Diabetes. 2017;66(suppl 1): 1192–P.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する